The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
Open accessAbstract
BACKGROUND: Cardiovascular risk is increased in patients with gout. We compared cardiovascular outcomes associated with febuxostat, a nonpurine xanthine oxidase inhibitor, with those associated with allopurinol, a purine base analogue xanthine oxidase inhibitor, in patients with gout and cardiovascular disease. METHODS: We conducted a multicenter, double-blind, noninferiority trial involving patients with gout and cardiovascular disease; patients were randomly assigned to receive febuxostat or allopurinol and were stratified according to kidney function. The trial had a prespecified noninferiority margin of 1.3 for the hazard ratio for the primary end point (a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or unstable angina with urgent revascularization). RESULTS: In total, 6190 patients underwent randomization, received febuxostat or allopurinol, and were followed for a median of 32 months (maximum, 85 months). The trial regimen was discontinued in 56.6% of patients, and 45.0% discontinued follow-up. In the modified intention-to-treat analysis, a primary end-point event occurred in 335 patients (10.8%) in the febuxostat group and in 321 patients (10.4%) in the allopurinol group (hazard ratio, 1.03; upper limit of the one-sided 98.5% confidence interval [CI], 1.23; P=0.002 for noninferiority). All-cause and cardiovascular mortality were higher in the febuxostat group than in the allopurinol group (hazard ratio for death from any cause, 1.22 [95% CI, 1.01 to 1.47]; hazard ratio for cardiovascular death, 1.34 [95% CI, 1.03 to 1.73]). The results with regard to the primary end point and all-cause and cardiovascular mortality in the analysis of events that occurred while patients were being treated were similar to the results in the modified intention-to-treat analysis. CONCLUSIONS: In patients with gout and major cardiovascular coexisting conditions, febuxostat was noninferior to allopurinol with respect to rates of adverse cardiovascular events. All-cause mortality and cardiovascular mortality were higher with febuxostat than with allopurinol. (Funded by Takeda Development Center Americas; CARES ClinicalTrials.gov number, NCT01101035 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Preliminary criteria for the classification of the acute arthritis of primary gout
Wallace, S. L., Robinson, H., Masi, A. T., Decker, J. L., Mccarty, D. J., & Yü, T. (1977) · Arthritis & Rheumatism · doi:10.1002/art.1780200320 · Cited by 1,432
Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout
Becker, M. A., Schumacher, H. R., Wortmann, R. L., MacDonald, P. A., Eustace, D., Palo, W. A., Streit, J., & Joseph-Ridge, N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050373 · Cited by 1,357
Self-citationKhanna, D., Khanna, P. P., Fitzgerald, J. D., Singh, M. K., Bae, S., Neogi, T., Pillinger, M. H., Merill, J., Lee, S., Prakash, S., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21773 · Cited by 728
Hicks, K. A., Tcheng, J. E., Bozkurt, B., Chaitman, B. R., Cutlip, D. E., Farb, A., Fonarow, G. C., Jacobs, J. P., Jaff, M. R., Lichtman, J. H., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000156 · Cited by 704
Independent Impact of Gout on Mortality and Risk for Coronary Heart Disease
Choi, H. K., & Curhan, G. (2007) · Circulation · doi:10.1161/circulationaha.107.703389 · Cited by 666
Schumacher, H. R., Becker, M. A., Wortmann, R. L., MacDonald, P. A., Hunt, B., Streit, J., Lademacher, C., & Joseph‐Ridge, N. (2008) · Arthritis Care & Research · doi:10.1002/art.24209 · Cited by 638
Self-citationRoddy, E., & Doherty, M. (2010) · Arthritis Research & Therapy · doi:10.1186/ar3199 · Cited by 370
Long-term Cardiovascular Mortality Among Middle-aged Men With Gout
Krishnan, E. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.10.1104 · Cited by 328
Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study
Schumacher, H. R., Becker, M. A., Lloyd, E., MacDonald, P. A., & Lademacher, C. (2008) · Rheumatology · doi:10.1093/rheumatology/ken457 · Cited by 251
Self-citation
Cited by
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Authors/Task Force Members:, McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2333 · Cited by 2,171
Dalbeth, N., Gosling, A. L., Gaffo, A., & Abhishek, A. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00569-9 · Cited by 1,338
2020 American College of Rheumatology Guideline for the Management of Gout
FitzGerald, J. D., Dalbeth, N., Mikuls, T., Brignardello‐Petersen, R., Guyatt, G., Abeles, A. M., Gelber, A. C., Harrold, L. R., Khanna, D., King, C., et al. (2020) · Arthritis Care & Research · doi:10.1002/acr.24180 · Cited by 983
2020 American College of Rheumatology Guideline for the Management of Gout
FitzGerald, J. D., Dalbeth, N., Mikuls, T., Brignardello‐Petersen, R., Guyatt, G., Abeles, A. M., Gelber, A. C., Harrold, L. R., Khanna, D., King, C., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41247 · Cited by 810
Dalbeth, N., Choi, H. K., Joosten, L. A. B., Khanna, P. P., Matsuo, H., Perez-Ruiz, F., & Stamp, L. K. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0115-y · Cited by 693
Yanai, H., Adachi, H., Hakoshima, M., & Katsuyama, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179221 · Cited by 595
Uric acid and cardiovascular disease
Ndrepepa, G. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.05.046 · Cited by 498
From purines to purinergic signalling: molecular functions and human diseases
Huang, Z., Xie, N., Illes, P., Di Virgilio, F., Ulrich, H., Semyanov, A., Verkhratsky, A., Sperlagh, B., Yu, S.-G., Huang, C., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00553-z · Cited by 489
Gout epidemiology and comorbidities
Singh, J. A., & Gaffo, A. (2020) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2020.04.008 · Cited by 456
Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease
Borghi, C., Agabiti-Rosei, E., Johnson, R. J., Kielstein, J. T., Lurbe, E., Mancia, G., Redon, J., Stack, A. G., & Tsioufis, K. P. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.07.006 · Cited by 435
Drosos, G. C., Vedder, D., Houben, E., Boekel, L., Atzeni, F., Badreh, S., Boumpas, D. T., Brodin, N., Bruce, I. N., González-Gay, M. Á., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221733 · Cited by 406
Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial
Kimura, K., Hosoya, T., Uchida, S., Inaba, M., Makino, H., Maruyama, S., Ito, S., Yamamoto, T., Tomino, Y., Ohno, I., et al. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.06.028 · Cited by 383
Uric acid and cardiovascular disease: A clinical review
Saito, Y., Tanaka, A., Node, K., & Kobayashi, Y. (2021) · Journal of Cardiology · doi:10.1016/j.jjcc.2020.12.013 · Cited by 374
New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity
Furuhashi, M. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00378.2020 · Cited by 361
Mackenzie, I. S., Ford, I., Nuki, G., Hallas, J., Hawkey, C. J., Webster, J., Ralston, S. H., Walters, M., Robertson, M., De Caterina, R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32234-0 · Cited by 352
Uric Acid and Cardiovascular Disease: An Update From Molecular Mechanism to Clinical Perspective
Yu, W., & Cheng, J.-D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.582680 · Cited by 344
Physiology of Hyperuricemia and Urate-Lowering Treatments
Benn, C. L., Dua, P., Gurrell, R., Loudon, P., Pike, A., Storer, R. I., & Vangjeli, C. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00160 · Cited by 319
Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis
Kimura, Y., Tsukui, D., & Kono, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212394 · Cited by 309
Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout
Hansildaar, R., Vedder, D., Baniaamam, M., Tausche, A.-K., Gerritsen, M., & Nurmohamed, M. T. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30221-6 · Cited by 270
Packer, M. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.08.015 · Cited by 95
Metadata
- Authors
- White, W. B., Saag, K. G., Becker, M. A., Borer, J. S., Gorelick, P. B., Whelton, A., Hunt, B., Castillo, M., & Gunawardhana, L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-03-29
- Volume
- 378
- Issue
- 13
- Pages
- 1200-1210
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2793103574
- Cited by
- 909
- References
- 21
- FWCI
- 69.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.